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Liver cancers are strongly linked to hepatitis B virus (HBV) and
hepatitis C virus (HCV). Egypt has the highest prevalence of HCV
worldwide and has rising rates of hepatocellular carcinoma
(HCC). Egypt’s unique nature of liver disease presents questions
regarding the distribution of HBV and HCV in the etiology of
HCC. Accordingly, a systematic search of MEDLINE, ISI Web of
Science, ScienceDirect and World Health Organisation databases
was undertaken for relevant articles regarding HBV and HCV
prevalence in Egypt among healthy populations and HCC cases.
We calculated weighted mean prevalences for HBV and HCV
among the populations of interest and examined differences in
prevalence by descriptive features, including age, year and geo-
graphic region. Prevalences for HBV and HCV were 6.7% and
13.9% among healthy populations, and 25.9% and 78.5% among
HCC cases. Adults had higher prevalences of both infections
(Adult HBV 5 8.0%, Child HBV 5 1.6%; Adult HCV 5 15.7%,
Child HCV 5 4.0%). Geographically, HBV was higher in the
south, whereas HCV was greater in the north (North HBV 5
4.6%, South HBV 5 11.7%; North HCV 5 15.8%, South HCV 5
6.7%). Among HCC cases, HBV significantly decreased over time
(p 5 0.001) while HCV did not, suggesting a shift in the relative
influences of these viruses in HCC etiology in Egypt. Our results
highlight large amounts of heterogeneity among the epidemiologi-
cal factors associated with liver disease in Egypt and underscore
the necessity of an integrated strategy for the successful preven-
tion of viral hepatitis infections and chronic liver disease.
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Hepatocellular carcinoma (HCC) comprises nearly 6% of all
incident cancer cases worldwide, with the overwhelming majority
occurring in the developing world.1 One of the least curable
malignancies, HCC is the third most frequent cause of cancer mor-
tality among men worldwide.1 Chronic infection with hepatitis B
virus (HBV) and hepatitis C virus (HCV) have been cited as, by
far, the most important etiologic agents.2 According to the World
Health Organisation (WHO), 350 million people are chronically
infected with HBV and 170 million are infected with HCV.3,4 The
relative importance of HBV and HCV as causative agents can
vary greatly from region to region and over time.1,5 Selecting
appropriate HCC prevention and control methods, therefore,
depends on understanding the dynamics of these agents in a speci-
fied geographic region.
Incidence of HCC in Egypt is currently increasing, which may
be the result of a shift in the relative importance of HBV and HCV
as primary risk factors.6–8 HCC is the second most frequent cause
of cancer incidence and mortality among men in Egypt.9 Hospital-
based studies from Egypt have reported an increase in the relative
frequency of all liver-related cancers in Egypt (>95% as HCC),
from 4.0% in 1993 to 7.3% in 2003.6–8 The Middle East Cancer
Consortium recently reported that the incidence rate among males
was 7 times greater than the next highest rate (among Israeli Jews)
and more than 3 times that reported in the United States Surveil-
lance Epidemiology and End Results summary.9 To explain this
trend it is necessary to understand the dynamics of HBV and HCV
in Egypt.
Before implementing the HBV vaccine in the 1980s, chronic
infection with HBV was widespread and considered the dominant
etiologic factor in HCC development.10 Childhood HBV immuni-
zation in Egypt today is estimated at 95–100%, thus making it
likely that HBV-related HCC will steadily decline over the next
few decades.11,12 This transition is not unique to Egypt. Many
eastern Mediterranean and Middle Eastern countries are experi-
encing a decline in HBV due to vaccination campaigns.13,14 What
sets Egypt apart is that this major public health achievement has
been eclipsed by the rise of the HCV epidemic, largely attributed
to the mass parenteral antischistosomal therapy (PAT) and other
iatrogenic exposures.15–18
Beginning in the 1950s, the Egyptian Ministry of Health tar-
geted schistosomiasis as its primary health problem, and mounted
a massive public health campaign to control it. At the time, the
best control method was through injecting individuals with PAT.
These campaigns were carried out at the community level as well
as in health facilities, where millions of Egyptians were treated
with PAT from the 1950s until the 1980s.18 Needle sterilization
was inadequate, and disposable needles were unavailable at that
time, leading to widespread transmission of HCV.16,18 Frank et al.
(2000) reported the strong relationship between PAT and country-
wide prevalence of HCV antibodies for the period 1961–1985.
They have cited the PAT campaign as ‘‘the world’s largest iatro-
genic transmission of blood-borne pathogens known to date.’’16
Egypt’s high levels of HCV are unique in comparison to nearby
countries, even those also heavily burdened by schistosomia-
sis.16,19 Though these countries also used PAT to control schisto-
somiasis, they never mounted any public health campaigns of sim-
ilar magnitude. Their control efforts were also more focused geo-
graphically and less population intensive.16 This could explain
why the burden of HCV in Egypt is so much greater than the sur-
rounding countries with similar schistosomiasis treatments.
Egypt is now plagued by the highest prevalence of HCV in the
world, with estimates ranging from 6 to 28% and a reported aver-
age of 13.8%.20,21 Recent investigations in Egypt have also
shown the increasing importance of HCV infection in the etiology
of HCC, now estimated to account for 40–50% of cases.6–8 The
future of HCC in Egypt and the magnitude of its socio-economic
burden will be a legacy of the country’s unique HCV epidemic
and the shifting dynamics of HBV and HCV. To date, there has
been no systematic review of the literature to synthesize the results
of published prevalence studies, including patterns over time.
There is, therefore, a need to calculate the fluctuating prevalences
of HBV and HCV in Egypt over the past 2 decades among a
healthy population-based sample; there is also a need to synthesize
data about HCC patients, using appropriate meta-analytic tools.
This paper aims to calculate weighted average prevalences of
HBV and HCV among 2 groups in Egypt from 1985 to the
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MEDLINE, ISI Web of Science, ScienceDirect and WHO re-
gional indexed databases were used to search for articles pub-
lished from January 1 1980 to October 31 2007, by means of the
MeSH terms of: ‘‘HCC and Egypt’’, ‘‘HBV and Egypt’’ and
‘‘HCV or hepacvirus and Egypt’. No language limitation was
imposed. For HCC studies, the time and place of subject recruit-
ment were cross-checked to avoid inclusion of the same cases in
multiple articles. Articles or reports from nonpeer-reviewed sour-
ces were not considered for this analysis.
Data analyzed
The key information abstracted from each study included:
(i) year(s) conducted, to account for the delay between field work
and publication; (ii) sample size; (iii) age range of participants,
with 18 years considered adults; (iv) geographic region of the
sample (upper or lower Egypt); (v) type of residence (urban or
rural); (vi) prevalence of hepatitis B surface antigen (HBsAg);
(vii) prevalence of anti-HCV antibodies (anti-HCV); and
(viii) type of HCV serology test used. We could not examine sex
differences in HBV and HCV infection, because too few studies
reported virus marker prevalence stratified by participant gender.
Similarly, we could not examine HBV and HCV coinfection as it
was rarely reported.
Inclusion and exclusion criteria
Healthy population-based studies included the following sample
populations: (i) voluntary blood donors (VBD); (ii) replacement
blood donors (RBD) typically from friends or blood relations;
(iii) healthy antenatal women; and (iv) community studies. We
excluded studies from the following special groups who were
assumed to be at special high risk: patients from sexually-trans-
mitted-disease clinics, thalassemia clinics, hospitalised patients,
professional or paid blood donors, sex workers, drug abusers, dial-
ysis patients and health care workers. Healthy population-based
studies with fewer than 100 participants were excluded from this
analysis.
HCC studies were limited to those examining incident cases to
avoid temporal ambiguity and the possibility that virus infection
may have occurred subsequent to the cancer diagnosis. HCC stud-
ies with fewer than 25 participants were excluded from this analy-
sis.
Eligible studies had to report prevalence of HBsAg and/or anti-
HCV. Studies were excluded if they failed to indicate the type
of test used to assess infection status and if the sensitivity and
specificity of the test was unknown. Information regarding HBV
infection and immunity status can be obtained from 4 common
seromarkers: HBsAg, anti-HBs, total hepatitis B core antibody
(anti-HBc) and IgM antibody to hepatitis B core antigen (IgM
anti-HBc). Of these markers, only HBsAg can identify the current
infection. A positive result indicates either active or chronic infec-
tion. Antibody markers cannot distinguish between naturally-
acquired immunity and vaccine-related immunity.22 Since we
wanted to measure the prevalence of naturally acquired infection,
HBsAg was the seromarker of interest. In addition, these tests are
inexpensive, simple to conduct, reliable and have been available
for a long time, allowing them to be fairly standard even in low-
resource settings.22
HCV infection status can be determined in 2 primary ways:
enzyme immunoassay (EIA) or polymerase chain reaction (PCR).
EIA techniques indicate the presence of antibody (anti-HCV)
while PCR can serve to confirm infection as well as measure viral
load. Both methods indicate ongoing infection and do not correlate
well with resolved infection. As with HBsAg, anti-HCV does not
distinguish between acute and chronic infection.23 While PCR
techniques tend to be more accurate, they are far more expensive
and, thus, infeasible for low-resource settings or areas with higher
prevalence. With a sensitivity greater than 95% and the availabil-
ity of standardized test kits, the WHO recommends EIA as the pri-
mary screening tool and suggests PCR be used for clinical and
case management purposes.23 For these reasons, it is rare to find
PCR tests reported in the literature from lower-resource settings
such as Egypt and we believe the results of EIA are sufficiently
consistent and reliable to be used in this analysis. Though some
studies did report both anti-HCV and PCR results, we only exam-
ined anti-HCV to limit bias due to varying test sensitivity and
specificity.
In addition, studies known or likely to have used first-genera-
tion ELISA for measuring anti-HCV were not included in this
meta-analysis due to known problems of sensitivity and specificity
of those assays.24 To date, there have been 3 generations of anti-
HCV EIAs, with the first developed in 1990. It suffered from poor
sensitivity and could not detect antibody prior to 4–6 months fol-
lowing initial infection. These tests also lacked sufficient specific-
ity, resulting in numerous false positive results. Second and third
generation tests have dramatically improved sensitivity (>95%)
and narrowed the window period between infection and anti-HCV
detection.23 Consequently, this analysis only considered reports
that used second or third generation anti-HCV EIAs, thereby
excluding 3 studies.
We also applied specific definitions when classifying Lower
and Upper Egypt as well as urban and rural settings.25 Lower and
Upper Egypt are broad geographic designations that respectively
refer to the north and south regions of Egypt. They are termed
according to the flow of the Nile, which runs south to north. Lower
Egypt is so termed, because it lies further downstream. Studies
have suggested that HCV prevalence differs between Lower Egypt
in the north and Upper Egypt in the south.6,7 Thus, we compared
studies of these 2 regions which comprised the vast majority of
published reports.
The Egyptian government classifies ‘‘governorates’’ (muha-
fazat) as either fully urban or joint urban and rural.25 The official
distinction between urban and rural is reflected in the lower tiers.
Fully urban governorates have no districts (markazes) which are
defined as a conglomeration of villages around a capital city. In
joint urban and rural governorates, therefore, urban locations are
comprised of each district’s capital city. All other locations in that
governorate are considered rural. Some urban governorates consist
of just 1 city (e.g. Cairo which has 23 urban neighborhoods). HCV
prevalence differences between urban and rural populations have
been suggested, so we systematically explored this hypothesis
using strict and consistent definitions.8,15–18,26
Statistical power
Two types of statistical power issues exist: small participant
sample size in individual studies and small sample size of studies,
particularly when stratified by subfactors of analysis (e.g. geo-
graphic region, age group, etc). Pooling 30 studies with sample
sizes of 50, for example, may not be as reliable as pooling 5 stud-
ies of 300 participants. Nevertheless, it is difficult to compare mul-
tiple studies of a particular geographic region to a single study in a
different region, regardless of sample size. Our sample size crite-
ria are somewhat arbitrary, but we did base our decision on what
is known about the difference in viral prevalence among healthy
population samples vs. HCC case samples in Egypt. Since little in-
formation is available on power calculations for these biomarkers
in Egypt, we took a more qualitative approach. Egypt experiences
a higher burden of HBV and HCV in its apparently healthy popu-
lation as compared to other countries, so we believe a minimum
sample size of 100 is adequate to detect statistical differences
between groups, provided the sample is a genuine representation
of the entire population of interest. Sample sizes of HCC studies
tend to be small because of the difficulty in obtaining participants.
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Since an overwhelming majority of HCC cases in Egypt, test posi-
tive for HBV and/or HCV, we believe sample sizes of 25 and
greater will provide sufficient statistical power.6,9
Meta-analysis
Data were analyzed according to 3 different categories: HBV
prevalence among healthy population-based samples, HCV preva-
lence among healthy population-based samples and HBV and
HCV prevalence among incident HCC cases. Summary prevalence
measures were calculated as averages weighted by individual
study sample size, using a standard method.26 These summary
measures were used to compare differences between sub-groups in
aggregate, as well as over time. Chi-square tests (a 5 0.05) were
performed to determine significant differences in prevalence with
respect to age category (child vs. adult), geographic location
(Upper vs. Lower Egypt), type of residence (urban vs. rural) and
study period (time; treated as a continuous variable).
Sensitivity analysis did not reveal any outlier or influential
prevalence estimates among the healthy population studies. One
study was found to be influential in lowering the estimate of anti-
HCV prevalence among HCC cases (Attia et al., 1996).27 Because
this study measured only anti-HCV and not HBsAg, it was con-
trolled for when we repeated our calculations to include only those
studies that measured both HBsAg and anti-HCV. We present
results from both calculations here.
All manipulations and analyses were performed using SAS v




The initial search generated >1,500 potential articles which
was refined to 200 relevant articles from MEDLINE (n 5 107),
WHO regional indexed databases (57), ISI Web of Science (34)
and ScienceDirect (2). A hand search of the reference lists of
selected articles identified a few additional relevant studies. Final
results from our search yielded a total of 39 unique peer-reviewed
studies meeting our inclusion/exclusion criteria. Several studies
measured both HBsAg and anti-HCV and some of them also
involved more than one study site, providing prevalence measures
for multiple population samples. Of these studies, 25 studied
healthy population-based samples and 14 were specific to HCC
cases. The healthy population-based studies included 12 with
HBsAg measurements and a total sample size of 7,597 and 24
with anti-HCV measurements and a total sample size of 42,457.
The 14 HCC case investigations with HBsAg and/or anti-HCV in-
formation had a total case population of 3,275. The time periods
of data varied: 1983–2002 for HBV among healthy population-
based samples, 1991–2004 for HCV studies among healthy popu-
lation-based samples and 1985–2005 for HCC studies. Data
abstracted from the studies are presented in Tables I, II. Results
from weighted means and chi-square tests for all categories among
HBV, HCV and HCC are presented in Table III.
HBsAg among healthy population-based samples
Overall, the prevalence of HBsAg among healthy population-
based samples was 6.7% (61.4%), with no significant variation
TABLE I – SUMMARY OF DATA ABSTRACTED FROM HEALTHY POPULATION LITERATURE
Biomarker Author [citation] Study period Population Region Residence Age n Prevalence (%)
HBsAg Sherif et al. [28] 1983 Community Lower Urban and Rural 181 yr 1,064 11.7
Sherif et al. [28] 1983 Community Lower Urban and Rural 181 yr 802 8.0
Gumie et al. [29] 1988–1990 VBD Lower Urban and Rural 181 yr 1,715 2.5
El-Sherbini et al. [30] 1991 School children Lower Urban and Rural <18 yr 198 1.5
El-Hawey et al. [31] 1991–1992 Community Lower Rural 181 yr 300 15.7
Arthur et al. [32] 1993 VBD Upper and Lower Urban and Rural 181 yr 1,030 12.7
Mabrouk et al. [33] 1993 Army recruits (male) Lower Urban and Rural 181 yr 297 1.7
Darwish et al. [34] 1993 VBD Lower Urban and Rural 181 yr 163 3.2
Darwish et al. [35] 1995 Community Lower Urban and Rural 181 yr 796 8.8
El-Sherbini et al. [30] 1995 School children Lower Rural <18 yr 300 0.7
Reda et al. [36] 1997 Community Lower Urban and Rural <18 yr 500 2.2
El-Sherbini et al. [30] 2002 School children Upper Urban <18 yr 470 1.5
Anti-HCV El-Sherbini et al. [37] 1991 School children Lower Rural <18 yr 138 15.9
El-Sherbini et al. [37] 1991 School children Lower Urban <18 yr 130 6.2
El-Sherbini et al. [37] 2002 School children Lower Urban <18 yr 470 2.1
Fathalla et al. [38] 1991–1992 VBD Upper and Lower Urban and Rural 181 yr 248 18.2
Arthur et al. [32] 1993 VBD Upper and Lower Urban and Rural 181 yr 2,644 24.8
Darwish et al. [34] 1993 VBD Lower Rural 181 yr 163 22.0
El-Sherbini et al. [37] 1994 School children Lower Rural <18 yr 294 2.0
Kumar et al. [39] 1994–1996 HPW Lower Urban and Rural 181 yr 499 15.0
Darwish et al. [35] 1995 Community Lower Urban and Rural 181 yr 796 40.3
Kassem et al. [40] 1996 HPW Lower Urban and Rural 181 yr 100 19.0
Mohamed et al. [41] 1997 Community Lower Rural <18 yr 1,823 8.2
Mohamed et al. [41] 1997 Community Upper Rural <18 yr 2,808 2.5
Stoszek et al. [42] 1997–2003 HPW Lower Urban and Rural 181 yr 2,587 15.8
Abdel Aziz et al. [43] 1999 Community Lower Rural 181 yr 3,999 24.3
Nafeh et al. [44] 1999 Community Upper Rural 181 yr 6,031 8.7
Tanaka et al. [45] 1999 VBD Upper and Lower Urban and Rural 181 yr 3,608 8.8
Rizk et al. [46] 2000–2002 HPW Lower Urban and Rural 181 yr 696 15.8
Bakr et al. [47] 2002 Community Lower Rural 181 yr 4,720 19.3
Mohamed et al. [48] 2002 Community Lower Rural 181 yr 2,425 18.5
Arafa et al. [20] 2002–2003 Community Lower Rural 181 yr 4,020 11.8
Raouf et al. [49] 2002–2003 HPW Lower Urban and Rural 181 yr 1,832 10.1
El-Sadawy et al. [50] 2003 Community Lower Rural 181 yr 842 27.4
El-Sadawy et al. [50] 2003 Community Lower Urban 181 yr 580 23.4
El-Raziky et al. [51] 2004 Community Lower Urban and Rural <18 yr 1,042 1.4
VBD, voluntary blood donors; HPW, healthy pregnant women.
Total n for HBsAg studies 5 7,597.
Total n for anti-HCV studies 5 42,457.
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TABLE II – SUMMARY OF DATA ABSTRACTED FROM HCC CASE LITERATURE
Author Study period Patient source Study n HBsAg1 (%) Anti-HCV1 (%)
Ahmed et al. [52] 1985 Tropical Medicine Department, Cairo University 25 28.0 –
El-Soudani et al. [53] 1989–1992 Al-Azhar University 38 73.7 –
El-Sherif et al. [54] 1991–1992 Mansoura University 30 30.0 70.0
El-Zayadi et al. [6] 1992–1995 Cairo Liver Center 321 38.6 85.7
Abdel-Wahab et al. [55] 1992–2005 Medical Research Institute, Alexandria University 1,012 – 79.6
Abdel-Wahab et al. [56] 1993 National Cancer Institute, Cairo 60 33.3 –
Angelico et al. [57] 1993–1995 National Cancer Institute, Cairo 135 15.6 67.4
Attia et al. [27] 1995 Ain Shams University Hospital 429 – 53.4
Hassan et al. [7] 1995–1996 National Cancer Institute, Cairo 33 15.2 75.8
Mabrouk et al. [58] 1995–1996 Ain Shams University Hospital 34 20.6 94.1
Yates et al. [12] 1997–1998 National Cancer Institute, Cairo 131 61.8 73.3
El-Zayadi et al. [59] 1998–2002 Cairo Liver Center 750 20.5 87.9
El-Kafrawy et al. [60] 1999–2002 Ain Shams University Hospital and NCI, Cairo 41 2.4 87.8
Ezzat et al. [61] 2003–2004 National Cancer Institute, Cairo 236 7.6 86.4
Total n for all studies 5 3,275.
All studies had a mean age between 45 and 60 yrs.
TABLE III – PREVALENCE ESTIMATES AND CHI-SQUARE RESULTS FOR ALL CATEGORIES OF ANALYSIS AND COMPARISON GROUPS
Population of analysis Category of analysis Comparison group Prevalence (%) # Studies Total n v2 p-value
HBsAg–healthy population Age Adult 8.0 8 6,129 <0.0001
Child 1.6 4 1,468
Time (total) 1983–1992 6.9 5 4,079 0.5900
1993–1995 6.5 7 3,518
Time (adult) 1983–1992 7.1 4 3,881 0.0027
1993–1995 9.3 4 2,248
Time (child) 1991–1993 1.5 1 198 0.8478
1994–1997 1.6 2 800
1998–2002 1.5 1 470
Region (total) Lower Egypt 4.6 10 5,503 <0.0001
Upper Egypt 11.7 1 1,064
Anti-HCV–healthy population Age Adult 15.7 17 35,752 <0.0001
Child 4.0 7 6,705
Time (total) 1990–1994 21.79 6 3,579 <0.0001
1995–1999 12.45 8 19,664
2000–2004 13.54 9 16,627
Time (adult) 1990–1994 24.7 3 3,017 <0.0001
1995–1999 14.8 6 15,033
2000–2004 14.8 7 15,115
Time (child) 1990–1994 6.4 3 562 <0.0001
1995–1999 4.8 2 4,631
2000–2004 1.0 2 1,512
Region (total) Lower Egypt 15.8 19 27,118 <0.0001
Upper Egypt 6.7 2 8,839
Region (adult) Lower Egypt 17.6 16 23,221 <0.0001
Upper Egypt 8.7 1 6,031
Region (child) Lower Egypt 5.1 7 3,897 <0.0001
Upper Egypt 2.5 1 2,808
Residence (total) Rural 13.4 10 27,100 <0.0001
Urban 5.5 3 1,180
Residence (adult) Rural 15.4 9 22,037 <0.0001
Urban 8.1 1 580
Residence (child) Rural 4.9 1 5,063 0.0003
Urban 3.0 2 600
HCC Cases (All studies) Infection prevalence HBV 25.9 12 1,834 <0.0001
HCV 78.5 10 3,140
Infection prevalence HBV (1985–1996) 32.7 8 676 <0.0001
HCV (1991–1996) 68.5 6 982
Infection prevalence HBV (1997–2004) 21.9 4 1,158 <0.0001
HCV (1997–2004) 85.9 4 1,158
HBV prevalence 1985–1996 32.7 8 676 <0.0001
1997–2004 21.9 4 1,158
HCV prevalence 1991–1996 68.5 6 982 <0.0001
1997–2004 85.9 4 1,158
HCC Cases (Only studies
measuring both HBsAg
and anti-HCV)
Infection prevalence (total) HBV 24.5 9 1,711 <0.0001
HCV 84.1 9 1,711
Infection prevalence (1991–1996) HBV 30.0 5 553 <0.0001
HCV 80.3 5 553
Infection prevalence (1997–2004) HBV 21.9 4 1,158 <0.0001
HCV 85.9 4 1,158
HBV prevalence 1991–1996 30.0 5 553 0.0010
1997–2004 21.9 4 1,158
HCV prevalence 1991–1996 80.3 5 553 0.2015
1997–2004 85.9 4 1,158
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over time (p 5 0.59) (Table III). When these studies were sepa-
rated according to age, the pattern was similar, however, preva-
lence was significantly higher among adults than children (p <
0.0001). Adults averaged a prevalence of 8.0% (61.7%), with
children averaging at 1.6% (60.3%), likely a function of the intro-
duction of the HBV vaccine.
Eleven of 12 healthy HBsAg studies provided information
regarding individuals from Lower Egypt with an average preva-
lence of 4.6% (61.3%), lower than that of the Upper Egypt study
11.7% (p < 0.0001). The one study from Upper Egypt may not be
representative, but it was a community-based sample of 1,064
individuals.
Anti-HCV among healthy population-based samples
Table III also presents the major findings from examining the
prevalence of anti-HCV among healthy population-based samples.
Overall, from 1990 to 2004 the prevalence was 13.9% (61.6%),
also significantly higher among adults (15.7% 6 1.8%) versus
children (4.0% 6 2.1%; p < 0.0001). Unlike findings with
HBsAg, however, anti-HCV prevalence seemed to vary over time,
both in summary and by age group (Fig. 1; Table III). Studies
from 1990 to 1994 showed a higher prevalence of 21.8 (63.3%)
when compared to the time periods 1995–1999 (12.5% 6 3.4%)
and 2000–2004 (13.5% 6 2.0%), which were not statistically dif-
ferent from one another. This trend continued for adults (p <
0.0001), but child studies suggested a continuing decline in preva-
lence (p < 0.0001; Fig. 1).
Analysis of anti-HCV by geographic region found the reverse
trend from what was observed with HBsAg (Fig. 1). Of the 24
total studies, 19 had specific information on Lower Egypt and 2
had specific measurements for Upper Egypt. Studies from Lower
Egypt showed a significantly higher prevalence (15.8% 6 1.8%)
than those from Upper Egypt (6.7% 6 2.9%) (p < 0.0001), a pat-
tern that remained stratifying by age group (Table III).
We compared studies of urban (n 5 3) and rural (n 5 10) popu-
lations. As the literature has suggested, there was a significantly
higher prevalence of anti-HCV among rural populations (13.4% 6
2.3%) compared to urban populations (5.5% 6 2.0%) (p <
0.0001). Again, this trend remained highly significant after strati-
fying by age group (Table III).
HBsAg and anti-HCV among HCC cases
Finally, Table III presents findings on the prevalence of HBsAg
and anti-HCV among HCC cases. There were 12 studies with
HBsAg data covering the time period 1985–2004 and 11 studies
with anti-HCV measurements spanning 1991–2004. The overall
prevalence of HBsAg was 25.9% (64.7%) and that of anti-HCV
was 78.5% (63.6%), a statistically significant difference (p <
0.0001). Both markers showed highly significant changes over
time, with HBsAg decreasing (1985–1996: 32.7% 6 5.2%; 1997–
2004: 21.9% 6 8.9%; p < 0.0001) and anti-HCV increasing
(1991–1996: 68.5% 6 6.6%; 1997–2004: 85.9% 6 2.6%; p <
0.0001) over time (Fig. 2).
Of the HCC studies included, 9 (n 5 1711) reported both
HBsAg and anti-HCV measurements. The above analysis for these
9 studies was repeated to reduce the possibility of bias due to early
generation ELISA tests, but results were similar. The overall prev-
alence of HBsAg was 24.5% (65.1%) and that of anti-HCV was
84.1% (62.4%). The decrease in HBsAg remained significant
(1991–1996: 30.0% 6 5.3%; 1997–2004: 21.9% 6 8.9%; p 5
0.001). A slight increase in anti-HCV prevalence was observed for
the revised group of studies, but it was no longer significant
FIGURE 1 – Prevalence of anti-HCV1 individuals. The top graph
shows prevalence over 3 time periods: 1990–1994, 1995–1999 and
2000–2004. The difference observed across time period was highly
significant (total, adult and child; p < 0.0001). The middle graph illus-
trates prevalence by geographic region (p < 0.0001). The bottom
graph shows prevalence by type of residence (p < 0.0001).
FIGURE 2 – Prevalence of HBsAg and anti-HCV1 among HCC
cases. The top graph shows prevalence over the 2 time periods: 1985–
1996 and 1997–2004. Differences across biomarkers as well as within
biomarkers over time were significant (p < 0.0001). The bottom graph
presents prevalence over the 2 time periods: 1991–1996 and 1997–
2004, using only studies that reported both HBsAg and anti-HCV
measurements. Differences between HBsAg and anti-HCV were sig-
nificant (p < 0.0001), as were differences within HBsAg prevalence
over time (p 5 0.001) but time differences within anti-HCV were not
significant (p5 0.2051).
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(1991–1996: 80.3% 6 4.3%; 1997–2004: 85.9% 6 2.6%; p 5
0.2015) (Fig. 2).
Discussion
This is the first systematic review and meta-analysis of hepatitis
B and C virus prevalence in Egypt and provides insights for under-
standing the past and future dynamics of liver disease there. For
HBV and HCV in healthy population-based samples, adults had a
significantly higher prevalence than children, supporting an inde-
pendent age cohort effect for both viruses. For HBV, it seems
likely that the cohort effect would be related to the introduction of
the hepatitis B vaccine in 1992, which was incorporated into the
expanded programme on immunization and is only given to chil-
dren, leaving adults unvaccinated at the time of program imple-
mentation. This explains the discrepancy in prevalence between
adults and children in our analysis. It should be noted that child-
hood HBV studies do not begin appearing until the vaccine pro-
gram had been introduced, as they were designed to evaluate the
vaccine’s success. Therefore, we were not able to compare child-
hood HBV prevalence between unvaccinated and vaccinated
groups, nor were we able to find reports of adult and child preva-
lence in the same individual study. Based on the timing of the
studies and the large difference in prevalence between adults and
children, however, it seems logical to conclude that the vaccine is
responsible for the consistently low levels of HBV in children and
higher prevalence among the unvaccinated adults.
The cohort effect seen in HCV is consistent with other studies
that report higher prevalences in age groups older than 30 yrs.8,15–17
These studies were focused on identifying risk factors for HCV
infection and often did not present prevalence results conducive
for use in the meta-analysis, which is why they were not included.
The age cohort observation is likely related to the early association
between the parenteral antischistosomiasis therapy (PAT) cam-
paign and HCV transmission. Oral therapies for schistosomiasis
were gradually adopted in the 1980’s, dramatically reducing trans-
mission.16,62 It is still unclear, however, what the rate of HCV
transmission is presently, in the absence of the original primary
route. Since several of the childhood HCV studies were late
enough that none of the children would have been exposed to the
PAT campaign, it does appear that HCV has continued to be trans-
mitted. It will be important to understand the emerging routes and
rates of transmission to effectively control the burden of liver dis-
ease in Egypt.
Our analysis confirmed reports of large scale geographic hetero-
geneity in HCV prevalence.6,7 We found prevalence to be signifi-
cantly higher in Lower Egypt as opposed to Upper Egypt, which
in turn supports the hypothesis of PAT as the dominant force driv-
ing the HCV epidemic. Individuals living in Lower Egypt experi-
enced a greater burden of schistosomiasis and therefore a greater
level of exposure to PAT.6,7 This is consistent with the only study
we found directly comparing HCV prevalence in a Lower Egypt
village and an Upper Egypt village (both rural). Mohamed et al.
(2006) conducted a childhood study in 1997, reporting a preva-
lence of 8.2% in Lower Egypt and 2.5% in Upper Egypt.48 This is
a slightly larger disparity than what the pooled analysis revealed
(Lower Egypt: 5.1%; Upper Egypt: 2.5%), but this does not neces-
sarily indicate inconsistency. Our results are unadjusted for year
to prevent over-stratification, whereas these findings were from
the same time period. Since we observed decreasing prevalence
among children over time and our analysis included data through
2002, we would expect the pooled result to be lower. We would
also expect greater variance in our estimates since we are pooling
studies from multiple, different study sites.
This is in contrast to what we saw with HBV, which seemed to
be higher in Upper Egypt versus Lower Egypt. Unfortunately, the
number studies of HBV prevalence in Upper Egypt was inad-
equate and we were unable to find any studies specifically compar-
ing HBV in Upper and Lower Egypt, so it is best not to draw too
many conclusions from that analysis.
We were also able to examine the relationship of HCV with
urban and rural populations, with results supporting the hypothesis
that HCV prevalence is higher among rural residents than urban
residents.8,15,63 Sherbini et al. (2006) examined HCV prevalence
among children in an urban setting in 1991 and 2002 and in a rural
setting in 1991 and 1994. The results indicated a higher HCV
prevalence in the rural region both times. In 1991, urban children
had a HCV prevalence of 6.2% while rural children experienced a
prevalence of 15.9%.30 Again, in 1994, Sherbini et al. reported a
prevalence of 5.8% in the rural setting and 2.1% in the 2002 urban
study.30 This trend is consistent with our results. We found a large
disparity among adults, with a prevalence of 15.4% and urban
prevalence of 8.1%. This corresponds with the 1991 studies and
that age cohort would all be adults at the time of more recent stud-
ies. The difference in rural and urban HCV prevalence was less
pronounced in the pooled estimates for children (rural: 4.9%;
urban: 3.0%). Again, this is logical considering the documented
decrease in HCV prevalence over time among children. Sherbini
et al. unfortunately do not have rural estimates more recent than
1994, making a direct comparison difficult. Nevertheless, the trend
observed in the Sherbini et al. study is supportive of our pooled
estimates. This finding is also in line with the PAT hypothesis;
that rural residents would have a greater burden of schistosomiasis
and therefore greater exposure to PAT.15–17,63
We were only able to find one childhood study that directly
examined HBV in urban and rural settings. Sherbini et al. (2007)
compared measurements from a 1995 study in a rural village with
a 2002 study in an urban setting (both in Lower Egypt). They
found a prevalence of 1.9% in the rural village and 1.1% in the
urban city, which were not statistically different from one
another.37 Because this was the only study to explicitly identify
separate urban and rural prevalences, we did not include it in the
meta-analysis. The finding is not surprising, however, since both
studies were conducted after the establishment of the HBV vacci-
nation program. The time difference between the 2 studies (rural:
1994; urban: 2002) could explain why the rural prevalence is
slightly higher. The vaccine program had only been in place for a
couple of years, so some unvaccinated children may have been
included.
Since most of the HCC studies were hospital-based, it is diffi-
cult to speculate on future effects even though more HCC cases
would be expected in rural regions. This is contrary to a recent
population-based HCC study from Lower Egypt that found cases
to be nearly twice as likely to come from urban versus rural
areas.64 Due to the significant lag time between viral infection and
development of HCC, it is possible that Egypt is witnessing the
end of a cohort of higher urban exposure that will soon transition
to a population dominated by rural exposure.
It was illuminating to examine the trends in HBV and HCV
prevalence over the past 20 years. We did see a slight increase
over time in HBV prevalence among adults from 7.1 to 9.3%. It is
likely that this may also be a product of the PAT campaign. The
same number of people were infected with HBV and HCV during
the PAT campaign; however, HBV only caused chronic infections
in 5% of infected individuals, whereas chronic HCV infection
developed in 70 to 80%.16,18 This can be explained by the natural
history of HBV, where the probability of developing chronic
infection decreases with age.10 Since most individuals receiving
PAT were 10–15 years or older, they were at less risk for develop-
ing persistent HBV infection.18 This could explain why we saw an
increase in HBV prevalence in the healthy population without a
similar increase among HCC cases. Among children, however,
HBV prevalence was low, probably due to the implementation of
earlier control measures followed by the vaccine. Infection levels
in children suggest that this infection may soon be an insignificant
element of the liver disease burden in Egypt.
Unlike HBV, prevalence of HCV showed greater variance over
time. Among both children and adults there was a general decline
695VIRAL HEPATITIS INFECTIONS IN EGYPT
in prevalence over time, with adults stabilizing at just below 15%
and children continuing to drop to nearly 1% by the period 2000–
2004. Detailed risk factor data are needed to further characterize if
time and space interactions are occurring and distinguish between
the effects of population migration, changing risk factor patterns,
etc. It would also be valuable to match these prevalence figures
with incidence studies to reconstruct the different epidemic
curves, shedding light on viral dynamics and guiding predictions
about future trends in infection.
A summary understanding of the status of HBV and HCV prev-
alence in healthy population-based samples should be compli-
mented by viral dynamics among HCC cases. Frequently the bur-
den of HBV and HCV cannot easily be quantified apart from its
chronic sequelae. By understanding the degree to which these
viruses contribute to HCC, it is possible to see the impact they
have on overall population health. The overall prevalence of HBV
among HCC cases was nearly 25%, with HCV infection preva-
lence as high as 84%. Some differences were noted over time
although not statistically significant, possibly a result of low
power. It seemed that HBV infection declined from a prevalence
of 30% between 1991 and 1996 to 22% between 1997 and 2004.
Conversely, HCV infection among HCC cases may have increased
slightly over this same time period from 80 to 86%. This is con-
sistent with the impact of the 2 different cohort effects. Current
cancer cases represent individuals being exposed to these viruses
20–30 years prior. These cases may represent the individuals at
the end of the pre-HBV vaccine period and the beginning of the
PAT campaign. Based on anticipated demographic changes, it
seems likely that prevalence of HBV will continue to decline and
HCV will continue to increase among HCC cases for the next few
decades. Indeed, results from mathematical models designed to
predict the future burden of HCV in Egypt are consistent with this
hypothesis.63 What happens after that will depend largely on the
new HCV incidence patterns in the absence of the PAT campaign.
Despite our extensive literature search, the specific search terms
used may not have captured all quality papers published in peer-
reviewed indexed journals. For this reason, we supplemented our
electronic search by a hand search of references from selected
articles, but there is always the possibility that some studies were
missed. We attempted to gain representative samples of the Egyp-
tian healthy population by accepting community-based samples,
but also included some large scale convenience samples such as
healthy pregnant women attending clinics and VBD. The inclusion
of VBD in systematic reviews has been questioned in a study at
Vellore, India where the HBV carrier rate was 0.7%, considered
artificially low because donors are a self-selected group and
HBV-positive people do not repeat donations.65 However,
another analysis of different population groups tested in Delhi,
found voluntary donors, replacement donors and ante-natal moth-
ers all had prevalences close to the overall mean.66 The extent to
which the HCC cases we reported upon are representative is also
unclear, since in most cases only hospital-based studies were
available. We did focus on cancer studies from the larger, nation-
ally recognized cancer centers, which serve as diagnostic and
treatment facilities for the overwhelming majority of cancer cases
throughout Egypt.
Only a large, national epidemiological study can provide a defin-
itive answer regarding the overall prevalence of hepatitis B and C
viruses in Egypt. Lacking such a national sample survey, our sys-
tematic review and meta-analysis of high quality studies previously
conducted provides a useful compromise. These findings highlight
the significance of continuing prevention of HBV through vaccina-
tion campaigns as well as the development of an integrated strategy
for the prevention of HCV infection that should include screening
of blood donations, safe injection practices and avoidance of
unnecessary injections. Controlling transmission of these 2 viruses
should effectively reduce the burden of HCC in Egypt.
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